Vokes E E
University of Chicago Cancer Research Center.
Oncology (Williston Park). 1995 Jun;9(6):565-74, 577; discussion 577-8, 581-.
Meta-analyses of randomized clinical studies comparing combination chemotherapy versus "best supportive care" for advanced non-small-cell lung cancer have revealed a small, but statistically significant survival advantage for patients who receive chemotherapy. However, overall increases in lifespan have been short, and the great majority of patients die within 1 year of diagnosis. In the last few years, several new drugs with promising activity have been identified. Of these, vinorelbine has already been shown to increase survival rates in randomized clinical trials. In particular, one such trial showed the combination of vinorelbine and cisplatin to result in statistically superior survival rates, compared with "standard" therapy of cisplatin and vindesine, and with single-agent vinorelbine. A second study comparing vinorelbine to fluorouracil/leucovorin also demonstrated a survival benefit for patients treated with vinorelbine. Therefore, the combination of vinorelbine and cisplatin represents one new option for initial therapy of newly diagnosed stage IV non-small-cell lung cancer.
对晚期非小细胞肺癌患者采用联合化疗与“最佳支持治疗”进行比较的随机临床研究的荟萃分析显示，接受化疗的患者生存期虽有小幅延长，但具有统计学意义。然而，总体寿命延长时间较短，绝大多数患者在确诊后1年内死亡。在过去几年中，已发现几种具有良好活性的新药。其中，长春瑞滨已在随机临床试验中显示可提高生存率。特别是，一项此类试验表明，与顺铂和长春地辛的“标准”疗法以及长春瑞滨单药治疗相比，长春瑞滨与顺铂联合使用可产生统计学上更优的生存率。另一项比较长春瑞滨与氟尿嘧啶/亚叶酸钙的研究也证明长春瑞滨治疗的患者有生存获益。因此，长春瑞滨与顺铂联合是新诊断的IV期非小细胞肺癌初始治疗的一种新选择。
